C12Y 207/01021
Thymidine kinase
Official title: Thymidine kinase (2.7.1.21)
C12Y207/01021 (Thymidine kinase) appears on 41 US grants and 112 published applications in this corpus.
Search patents in C12Y- Granted patents
- 41
- Published applications
- 112
- Assignees
- 67
- Inventors
- 226
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 1 |
| 2003 | 1 | 0 |
| 2004 | 1 | 1 |
| 2005 | 0 | 2 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 4 |
| 2012 | 1 | 2 |
| 2013 | 0 | 2 |
| 2014 | 1 | 7 |
| 2015 | 0 | 5 |
| 2016 | 1 | 2 |
| 2017 | 3 | 9 |
| 2018 | 5 | 5 |
| 2019 | 6 | 8 |
| 2020 | 2 | 7 |
| 2021 | 1 | 7 |
| 2022 | 6 | 11 |
| 2023 | 4 | 10 |
| 2024 | 4 | 11 |
| 2025 | 1 | 5 |
| 2026 | 2 | 12 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological diseases2 Jun 2026US 12,642,817 B2The Johns Hopkins University
- DNA, expression vector, transcript, cell, pharmaceutical composition, and medicine13 Jan 2026US 12,521,450 B2Hitachi, Ltd.
- Gene therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes23 Sep 2025US 12,419,970 B2The Trustees of Columbia University in the City of New York
- Cyclin G1 inhibitors and related methods of treating cancer24 Dec 2024US 12,173,041 B2Delta Next-Gene, LLC
- Development of recombinant chicken IGY SCFV antibody raised against human thymidine kinase 1 expressed in prokaryotic cells and use thereof1 Oct 2024US 12,103,980 B2Sino-Swed Tongkang Bio-Tech (Shenzhen) Limited
- Functional nucleic acid molecule and method20 Aug 2026US 2026/0241035 A1The University Court of the University of Edinburgh
- Ovarian cancer risk prediction13 Aug 2026US 2026/0235608 A1Arocell AB
- Methods for treating liver cancer by genomic targeting9 Jul 2026US 2026/0191996 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Vector for expression of chimeric antigen receptor and uses thereof11 Jun 2026US 2026/0158067 A1GenVivo, Inc.
- Pharmaceutical composition for treating spinocerebellar ataxia11 Jun 2026US 2026/0159839 A1National University Corporation Tokyo Medical and Dental University
Most cited
By later US patents
- Transgenic macrophages, chimeric antigen receptors, and associated methods21US 10,415,017 B2Thunder Biotech Inc. · 2019
- Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy12US 6,716,824 B12004
- Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases11US 5,856,153 ACayla · 1999
- Methods of cytotoxic gene therapy to treat tumors10US 10,350,275 B2Advantagene, Inc. · 2019
- Recombinant adenovirus with increased safety and anticancer activities, and use thereof9US 10,077,430 B2National Cancer Center · 2018